Works cited What you need to know about Ozempic and other drugs being used for weight loss, accessed April 23, 2025, Semaglutide - StatPearls - NCBI Bookshelf, accessed April 23, 2025, Wegovy for the Treatment of Chronic Weight Management, US - Clinical Trials Arena, accessed April 23, 2025, CENTER FOR DRUG EVALUATION AND RESEARCH - accessdata.fda.gov, accessed April 23, 2025, Wegovy (semaglutide) injection - accessdata.fda.gov, accessed April 23, 2025, Wegovy: Uses, Side Effects, Dosage, Warnings - Drugs.com, accessed April 23, 2025, Wegovy (semaglutide): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing, accessed April 23, 2025, Prescription Weight Loss Medication | Wegovy (semaglutide) Injection 2.4 mg, accessed April 23, 2025, Wegovy | European Medicines Agency (EMA), accessed April 23, 2025, FDA approves Ozempic (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease - Novo Nordisk, accessed April 23, 2025, Ozempic (semaglutide): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing, accessed April 23, 2025, Ozempic: Cost, dosage, side effects, uses, and more - Medical News Today, accessed April 23, 2025, Mounjaro for weight loss: Price, side effects, and more - Medical News Today, accessed April 23, 2025, Zepbound for Weight Loss: Uses, Dosage, Side Effects - Drugs.com, accessed April 23, 2025, Tirzepatide: Uses, Dosage, Side Effects & Warnings - Drugs.com, accessed April 23, 2025, Mounjaro (tirzepatide): Uses, Dosage, Side Effects & Coupons - Drugs.com, accessed April 23, 2025, Zepbound approved by FDA as first sleep apnea medication, accessed April 23, 2025, HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZEPBOUND safely and effe - accessdata.fda.gov, accessed April 23, 2025, FDA Approves First Medication for Obstructive Sleep Apnea, accessed April 23, 2025, Zepbound: Dosage, side effects, uses, and more - Medical News Today, accessed April 23, 2025, FDA approves Zepbound (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity - Eli Lilly Investors, accessed April 23, 2025, Zepbound (tirzepatide) Injection for Adults with Obesity or OSA, accessed April 23, 2025, Lilly's Zepbound (tirzepatide) superior to Wegovy (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs
If your healthcare team determines a medication hold is appropriate, the duration should be individualized based on your specific medication, dosing frequency, and clinical factors
Terushkin empowers individuals to achieve sustainable weight loss and improved overall health
Average weight loss was approximately 1419%
Am I eligible for Wegovy
Diabetes Care 19 , 580586 (1996)
